CARILEX MEDICAL INC.(TW:7726)
NT$32.15+1.20 (+3.88%)
TW:7726
CARILEX MEDICAL INC. financials statements
NT$32.15
At close:+1.20 (+3.88%)
CARILEX MEDICAL INC. (7726) Ratios
CARILEX MEDICAL INC. Ratios
TW:7726's free cash flow for Q2 2026 was NT$28.27M. For the 2026 fiscal year, TW:7726's free cash flow was decreased by NT$-2.71M and operating cash flow was NT$30.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.95 | 3.32 | 2.64 | 2.27 | 2.05 |
| Quick Ratio | 1.52 | 1.95 | 1.46 | 1.20 | 1.30 |
| Cash Ratio | 1.01 | 1.15 | 0.96 | 0.88 | 0.82 |
| Solvency Ratio | 0.01 | 0.29 | 0.34 | 0.27 | 0.23 |
| Operating Cash Flow Ratio | 0.21 | 0.21 | 0.01 | 0.22 | 0.46 |
| Short-Term Operating Cash Flow Coverage | 0.36 | 0.50 | 0.04 | 0.51 | 1.58 |
| Net Current Asset Value | NT$ 189.24M | NT$ 266.14M | NT$ 284.78M | NT$ 157.01M | NT$ 134.03M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.32 | 0.16 | 0.13 | 0.25 | 0.24 |
| Debt-to-Equity Ratio | 0.59 | 0.22 | 0.21 | 0.43 | 0.49 |
| Debt-to-Capital Ratio | 0.37 | 0.18 | 0.17 | 0.30 | 0.33 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.84 | 1.39 | 1.55 | 1.75 | 2.05 |
| Debt Service Coverage Ratio | 0.04 | 0.77 | 1.29 | 0.74 | 0.98 |
| Interest Coverage Ratio | -17.04 | 2.01 | 32.67 | 12.95 | 48.47 |
| Debt to Market Cap | 0.16 | 0.07 | 0.04 | 0.05 | 0.05 |
| Interest Debt Per Share | 8.60 | 4.41 | 4.45 | 6.22 | 7.32 |
| Net Debt to EBITDA | 9.60 | -1.53 | -1.28 | -0.48 | -0.67 |
| Profitability Margins | |||||
| Gross Profit Margin | 29.27% | 42.78% | 42.19% | 42.54% | 43.48% |
| EBIT Margin | -10.89% | 5.18% | 12.46% | 11.15% | 11.06% |
| EBITDA Margin | -1.60% | 12.15% | 16.91% | 16.75% | 15.36% |
| Operating Profit Margin | -12.63% | 0.86% | 11.88% | 5.24% | 13.47% |
| Pretax Profit Margin | -11.63% | 4.75% | 12.10% | 10.75% | 10.78% |
| Net Profit Margin | -8.56% | 3.83% | 9.53% | 8.61% | 8.34% |
| Continuous Operations Profit Margin | -8.56% | 3.83% | 9.53% | 8.61% | 8.34% |
| Net Income Per EBT | 73.57% | 80.62% | 78.75% | 80.07% | 77.37% |
| EBT Per EBIT | 92.12% | 552.41% | 101.90% | 205.12% | 80.01% |
| Return on Assets (ROA) | -5.43% | 2.93% | 8.18% | 6.96% | 7.76% |
| Return on Equity (ROE) | -9.96% | 4.08% | 12.64% | 12.17% | 15.89% |
| Return on Capital Employed (ROCE) | -13.70% | 0.89% | 15.27% | 6.57% | 21.16% |
| Return on Invested Capital (ROIC) | -6.71% | 0.60% | 10.19% | 4.05% | 13.01% |
| Return on Tangible Assets | -5.58% | 3.05% | 8.49% | 7.28% | 7.77% |
| Earnings Yield | -3.48% | 1.84% | 3.67% | 2.38% | 3.26% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.81 | 4.73 | 6.29 | 8.14 | 5.24 |
| Payables Turnover | 17.68 | 19.09 | 8.80 | 10.46 | 6.87 |
| Inventory Turnover | 2.49 | 1.23 | 1.27 | 1.23 | 1.74 |
| Fixed Asset Turnover | 6.28 | 12.21 | 14.75 | 7.09 | 7.36 |
| Asset Turnover | 0.63 | 0.77 | 0.86 | 0.81 | 0.93 |
| Working Capital Turnover Ratio | 1.39 | 1.23 | 1.93 | 1.84 | 2.15 |
| Cash Conversion Cycle | 221.54 | 353.84 | 304.52 | 307.82 | 226.17 |
| Days of Sales Outstanding | 95.90 | 77.21 | 58.07 | 44.83 | 69.66 |
| Days of Inventory Outstanding | 146.29 | 295.75 | 287.92 | 297.89 | 209.66 |
| Days of Payables Outstanding | 20.65 | 19.12 | 41.47 | 34.90 | 53.15 |
| Operating Cycle | 242.19 | 372.96 | 345.99 | 342.72 | 279.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.29 | 1.50 | 0.12 | 1.98 | 5.77 |
| Free Cash Flow Per Share | 1.78 | 1.32 | -0.28 | 0.29 | 5.66 |
| Dividend Paid and CapEx Coverage Ratio | 2.11 | 0.64 | 0.29 | 1.17 | 1.58 |
| Capital Expenditure Coverage Ratio | 4.43 | 8.54 | 0.29 | 1.17 | 50.39 |
| Operating Cash Flow Coverage Ratio | 0.27 | 0.35 | 0.03 | 0.32 | 0.80 |
| Operating Cash Flow to Sales Ratio | 0.14 | 0.07 | 0.00 | 0.10 | 0.20 |
| Free Cash Flow Yield | 4.33% | 3.01% | -0.39% | 0.40% | 7.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -28.67 | 54.32 | 29.24 | 42.08 | 30.72 |
| Price-to-Sales (P/S) Ratio | 2.46 | 2.08 | 2.60 | 3.62 | 2.56 |
| Price-to-Book (P/B) Ratio | 2.86 | 2.22 | 3.45 | 5.11 | 4.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 23.10 | 33.24 | -257.76 | 249.64 | 12.86 |
| Price-to-Operating Cash Flow Ratio | 17.88 | 29.35 | 617.35 | 36.70 | 12.61 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | -0.81 | 0.67 | -1.56 | -0.78 |
| Enterprise Value Multiple | -143.76 | 15.62 | 14.10 | 21.11 | 16.01 |
| Enterprise Value | 780.33M | 667.59M | 1.11B | 1.19B | 953.37M |
| EV to EBITDA | -143.76 | 15.62 | 14.10 | 21.11 | 16.01 |
| EV to Sales | 2.30 | 1.90 | 2.38 | 3.53 | 2.46 |
| EV to Free Cash Flow | 21.65 | 30.28 | -236.34 | 244.04 | 12.34 |
| EV to Operating Cash Flow | 16.76 | 26.73 | 566.06 | 35.88 | 12.10 |
| Tangible Book Value Per Share | 13.60 | 18.77 | 19.91 | 13.14 | 14.88 |
| Shareholders’ Equity Per Share | 14.33 | 19.82 | 21.10 | 14.24 | 14.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.26 | 0.19 | 0.21 | 0.20 | 0.23 |
| Revenue Per Share | 16.68 | 21.12 | 28.00 | 20.13 | 28.41 |
| Net Income Per Share | -1.43 | 0.81 | 2.67 | 1.73 | 2.37 |
| Tax Burden | 0.74 | 0.81 | 0.79 | 0.80 | 0.77 |
| Interest Burden | 1.07 | 0.92 | 0.97 | 0.96 | 0.97 |
| Research & Development to Revenue | 0.07 | 0.07 | 0.04 | 0.04 | 0.08 |
| SG&A to Revenue | 0.35 | 0.35 | 0.26 | 0.33 | 0.22 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Income Quality | -1.18 | 1.49 | 0.03 | 1.14 | 1.89 |
Currency in TWD
